{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:49:00Z","timestamp":1790516940252,"version":"4.1.0"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Invasive mycotic infections have become more common during recent decades, posing an increasing threat to public health. However, despite the growing needs, treatments for invasive fungal infections remain unsatisfactory and are limited to a small number of antifungals. The aim of this study was to identify novel fungal cell wall inhibitors from a library of small chemical compounds using a conditional protein kinase C (PKC)-expressing strain of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Aspergillus nidulans<\/jats:named-content>\n            sensitive to cell wall-active agents. Eight \u201chit\u201d compounds affecting cell wall integrity were identified from a screen of 35,000 small chemical compounds. Five shared a common basic molecular structure of 4-\n            <jats:underline>c<\/jats:underline>\n            hloro-6-\n            <jats:underline>a<\/jats:underline>\n            rylamino-7-\n            <jats:underline>n<\/jats:underline>\n            itro-\n            <jats:underline>be<\/jats:underline>\n            nzo\n            <jats:underline>f<\/jats:underline>\n            urazane (CANBEF). The most potent compound, CANBEF-24, was characterized further and was shown to inhibit the growth of pathogenic\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Aspergillus<\/jats:named-content>\n            ,\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida<\/jats:named-content>\n            ,\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Fusarium<\/jats:named-content>\n            , and\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Rhizopus<\/jats:named-content>\n            isolates at micromolar concentrations but not to affect the growth of mammalian cell lines. CANBEF-24 demonstrated strong synergy in combination with caspofungin, an antifungal that inhibits cell wall biosynthesis. Genetic and biochemical analyses with\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Aspergillus nidulans<\/jats:named-content>\n            and\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Saccharomyces cerevisiae<\/jats:named-content>\n            indicated that CANBEFs selectively inhibit fungal rRNA maturation and protein synthesis, suggesting that their effect on the cell wall is indirect. CANBEFs were nontoxic in insect (\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Galleria mellonella<\/jats:named-content>\n            ,\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Drosophila melanogaster<\/jats:named-content>\n            ) and mouse models of fungal infection. Preliminary evidence showing no therapeutic benefit in these models suggests that further cycles of optimization are needed for the development of this novel class of compounds for systemic use.\n          <\/jats:p>","DOI":"10.1128\/aac.00850-15","type":"journal-article","created":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T02:29:57Z","timestamp":1436236197000},"page":"5631-5640","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":22,"title":["Identification and Characterization of a Novel Family of Selective Antifungal Compounds (CANBEFs) That Interfere with Fungal Protein Synthesis"],"prefix":"10.1128","volume":"59","author":[{"given":"Gabriel","family":"Mircus","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Albert","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Ben-Yaakov","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dodo","family":"Chikvashvili","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yona","family":"Shadkchan","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Osherov","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e32832db9f3"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S40160"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004404"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)82003-6"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/322606"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12081"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e32835ebcb7"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp270"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00294-007-0129-y"},{"key":"e_1_3_3_11_2","volume-title":"Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard","author":"CLSI","year":"2008","unstructured":"CLSI. 2008. M38-A2. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"2"},{"key":"e_1_3_3_12_2","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard","author":"CLSI","year":"2008","unstructured":"CLSI. 2008. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1006\/fgbi.2000.1236"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/genetics\/155.2.647"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.7.2490-2496.2004"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.1.75"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.104.6.1495"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1534\/g3.112.003400"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.10.5243-5246.2005"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(03)00476-3"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00466-5"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-0674(99)80053-2"},{"key":"e_1_3_3_23_2","volume-title":"Antifungal agents: advances and problems. Progress in drug research","author":"Jucker E","year":"2003","unstructured":"Jucker E, Polack A. 2003. Antifungal agents: advances and problems. Progress in drug research. Birkh\u00e4user Verlag, Basel, Switzerland."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.744"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1021\/np300704s"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612811319200012"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.1.48"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2011.551116"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.01.051"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3287"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep02475"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0061(19980130)14:2<115::AID-YEA204>3.0.CO;2-2"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00850-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00850-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:58:02Z","timestamp":1645484282000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00850-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1128\/AAC.00850-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.00850-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"2015-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-06-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-08-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}